Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML.
about
Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemiaThe Broad Anti-AML Activity of the CD33/CD3 BiTE Antibody Construct, AMG 330, Is Impacted by Disease Stage and RiskExpression of CD33 is a predictive factor for effect of gemtuzumab ozogamicin at different doses in adult acute myeloid leukaemia.Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531.Genetics of CD33 in Alzheimer's disease and acute myeloid leukemia.Acute myeloid leukemia stem cells and CD33-targeted immunotherapyCD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemiaSiglec-8 as a drugable target to treat eosinophil and mast cell-associated conditions.Clinical significance of CD33 nonsynonymous single-nucleotide polymorphisms in pediatric patients with acute myeloid leukemia treated with gemtuzumab-ozogamicin-containing chemotherapyGemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology GroupCD33 Expression and Its Association With Gemtuzumab Ozogamicin Response: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531.Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicinCellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML.Molecular therapeutic approaches for pediatric acute myeloid leukemia.Children's Oncology Group's 2013 blueprint for research: acute myeloid leukemiaNovel therapies for children with acute myeloid leukaemia.Pediatric relapsed or refractory leukemia: new pharmacotherapeutic developments and future directions.Overview of therapy and strategies for optimizing outcomes in de novo pediatric acute myeloid leukemia.An extensive pharmacokinetic, metabolic and toxicological review of elderly patients under intensive chemotherapy for acute myeloid leukemia.Update on antigen-specific immunotherapy of acute myeloid leukemia.How validated receptor occupancy flow cytometry assays can impact decisions and support drug development.Dose-related efficacy and toxicity of gemtuzumab ozogamicin in pediatric acute myeloid leukemia.Gemtuzumab ozogamicin in acute myeloid leukemia.Antibody-Based Treatment of Acute Myeloid Leukemia.Acute myeloid leukemia targets for bispecific antibodies.Targeting myelogenous leukemia stem cells: role of the circulation.The prognostic effect of high diagnostic WT1 gene expression in pediatric AML depends on WT1 SNP rs16754 status: report from the Children's Oncology Group.Disease Characteristics and Prognostic Implications of Cell-Surface FLT3 Receptor (CD135) Expression in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group.CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531.A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia.Polo-like kinase inhibitor volasertib marginally enhances the efficacy of the novel Fc-engineered anti-CD33 antibody BI 836858 in acute myeloid leukemia.Biting back: BiTE antibodies as a promising therapy for acute myeloid leukemia.
P2860
Q27853019-3713DC8F-ADC2-4853-9F5B-250BF66298E1Q28547458-22C078E5-922B-4FC7-98E3-D03093324E7CQ33643108-95084134-7759-454B-84FD-E202CF6AB7DFQ34172042-411DD3AC-1915-49EE-8909-7BA287C58EACQ35837399-CE40BB88-BB6C-428A-A9C7-1C7C876C6252Q36058588-0B728DFF-2298-49BD-8810-FDB983D211A2Q36279306-DA95FDDD-D2A5-403E-B790-DF2469A424CAQ36655884-759CB59C-74FC-458F-A01C-FD6C18CF90B6Q36698173-ACECA22C-4CC7-455F-9B67-46DE660207D1Q36805474-2ACAD33E-E8AB-4FDE-9F64-629D67F1A5E8Q36914445-8D500514-C9A5-4FF3-AEA3-37766E2FBEEDQ36932014-8CBA1E77-EE4A-4B42-81B9-3937B333C793Q37512086-CB784469-9272-473C-9032-0E038A7474DFQ37643136-C26C1FC2-5846-41C8-B0BF-4F2BA1824ACEQ38068816-C0998EF3-9661-416D-979F-9DA2DBEB6D88Q38096798-49E77785-E185-41CA-9D8E-234BE7018850Q38097334-DE1A9BF6-9B80-409D-B2E1-C1583616A612Q38196743-6D781F2B-F2C0-4AFB-93E3-ED95C4AF7F69Q38285621-3B70DB32-AFAA-45CE-84F6-32836CBA0E70Q38432103-B96FDCFA-D03D-4E02-B21F-EF4445226351Q38579129-A5A6776E-AAFA-4FF6-9898-2D382D6AED1DQ38662393-DA8652D6-618F-4C7E-ABAC-F43B862880BBQ38728718-6AC7D923-F5A0-4222-A6BE-4339000743B6Q38979277-34AA789D-CAD7-456A-9800-A314FBE2EEDBQ39117761-DA769796-F007-459B-8648-04043BEF2A1BQ41860215-5A89D405-E75C-41BD-9EEB-5C16B6179D23Q45012427-B48D1B99-22BE-4452-9FE1-D1FD7E1D0306Q46169481-F9124098-01E3-4D21-9E70-39CCA3A454D9Q46426075-7F4A5785-00BE-4997-A111-C0E5795B0321Q47563820-ECB32B8D-ABB7-4D64-8735-1F9E1FE9DA6DQ52668213-7C3D6395-1D08-43F0-8519-D9E498D58058Q53063068-434712F8-3FFF-42D9-B56E-94B38C29AD18
P2860
Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Correlation of CD33 expression ...... chemotherapy in childhood AML.
@ast
Correlation of CD33 expression ...... chemotherapy in childhood AML.
@en
type
label
Correlation of CD33 expression ...... chemotherapy in childhood AML.
@ast
Correlation of CD33 expression ...... chemotherapy in childhood AML.
@en
prefLabel
Correlation of CD33 expression ...... chemotherapy in childhood AML.
@ast
Correlation of CD33 expression ...... chemotherapy in childhood AML.
@en
P2093
P2860
P1433
P1476
Correlation of CD33 expression ...... chemotherapy in childhood AML.
@en
P2093
Alan Gamis
Betsy Hirsch
Irwin D Bernstein
Janet Franklin
Jessica A Pollard
Michael Loken
Phoenix A Ho
Robert B Gerbing
Roland B Walter
Soheil Meshinchi
P2860
P304
P356
10.1182/BLOOD-2011-12-398370
P407
P577
2012-02-29T00:00:00Z